Publications
Detailed Information
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Young-Yim | - |
dc.contributor.author | Park, Chul-Kee | - |
dc.contributor.author | Kim, Seung-Ki | - |
dc.contributor.author | Phi, Ji-Hoon | - |
dc.contributor.author | Kim, Jin-Hyun | - |
dc.contributor.author | Kim, Chae-Yong | - |
dc.contributor.author | Wang, Kyu-Chang | - |
dc.contributor.author | Cho, Byung-Kyu | - |
dc.date.accessioned | 2011-10-17T04:34:09Z | - |
dc.date.available | 2011-10-17T04:34:09Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Oncol Rep 21:1413-1419,2009 | en |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | https://hdl.handle.net/10371/74202 | - |
dc.description.abstract | CKD-602 7-[2-(N-isopropylamino)ethyl]-(20S)-
camptothecin, belotecan) is a synthetic water-soluble camptothecin derivative and topoisomerase inhibitor that has been shown to have clinical anticancer effect against ovarian and lung cancer. We studied its anticancer effects on four human glioma cell lines, U87 MG, U343 MG, U251 MG and LN229. Cell viability was quantified by a modified 2-(2- methoxy-4-nitropheyl)-3-(4-nitropheyl)-5-(2,4-disulfophenyl) -2H-tetrazolium, monosodium salt and significant time- and dose-dependent cytotoxicity was observed in all cell lines. Susceptibility to CKD-602 at 48 h after treatment varied among the four cell lines and their IC50 value was as follows: 9.07 nM (95% CI 0.18-37.42) for LN229, 14.57 nM (95% CI 0.86-47.33) for U251 MG, 29.13 nM (95% CI 0.35-101.23) for U343 MG, and 84.66 nM (95% CI 34.63-148.25) for U87 MG. CKD-602 induced cell cycle arrest at G2 phase and produced antiproliferative activity and apoptosis in all cell lines. Thus, CKD-602 showed a significant anticancer effect on glioma cells in vitro and is a promising candidate for further studies on malignant gliomas. | en |
dc.description.sponsorship | This study received grant support from the National R&D Program for Cancer Control, Ministry of Health & Welfare, Grant no. 0520300 (B-K. Cho), Korea Science and Engineering Foundation (KOSEF) Grant no. R01-2008-000-20268-0 (S-K. Kim). We thank Chong Kun Dang Pharmaceutical Corporation for providing CKD-602. | en |
dc.language.iso | en | en |
dc.publisher | Spandidos Publications | en |
dc.subject | belotecan | en |
dc.subject | camptothecin analogue | en |
dc.subject | CKD-602 | en |
dc.subject | malignant glioma | en |
dc.subject | topoisomerase 1 inhibitor | en |
dc.title | CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 김영임 | - |
dc.contributor.AlternativeAuthor | 박철기 | - |
dc.contributor.AlternativeAuthor | 김승기 | - |
dc.contributor.AlternativeAuthor | 피지훈 | - |
dc.contributor.AlternativeAuthor | 김진현 | - |
dc.contributor.AlternativeAuthor | 김채용 | - |
dc.contributor.AlternativeAuthor | 왕규창 | - |
dc.contributor.AlternativeAuthor | 조병규 | - |
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.